ARHGDIB has been found to function as a positive regulator of cancer progression in ovarian [44], breast [45], colorectal [43] and gastric cancers [46], and as a negative regulator in Hodgkin's lymphoma [47], bladder cancer [48, 49] and lung cancer [50]. Here, ARHGDIB is linked to cancer.